注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Acumen Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司致力于开发一种针对阿尔茨海默病(AD)根本原因的疾病改善方法。该公司专注于推进靶向免疫治疗候选药物ACU193,并在早期AD患者中建立机制证据。该公司的ACU193是一种人源化单克隆抗体,选择性靶向抗淀粉样蛋白β肽低聚物(AbOs),在体外试验中显示出功能和保护作用,并在包括转基因在内的多种动物物种中显示出体内安全性和药理活性AD的模型。该公司的治疗方法侧重于靶向AbOs,这是一种相对于抗体单体和淀粉样蛋白斑块的毒性和致病性抗体形式。它正在开发用于静脉注射(IV)的ACU193,每4周给药一次,用于治疗早期AD,目前处于I期临床试验阶段。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Sean Stalfort | 52 | 2018 | Independent Chairman of the Board |
Jeffrey L. C. Ives | 71 | 2014 | Independent Director |
Kimberlee Cobleigh Drapkin | 54 | 2022 | Independent Director |
Laura Stoppel | 36 | 2020 | Independent Director |
Nathan B. Fountain | 60 | 2021 | Independent Director |
Jeffrey L. Cummings | 73 | - | Member of Clinical & Scientific Advisory Board |
Reisa Sperling | - | - | Member of Clinical & Scientific Advisory Board |
Stephen Salloway | - | - | Member of Clinical & Scientific Advisory Board |
Cynthia A. Lemere | - | - | Member of Clinical & Scientific Advisory Board |
Colin Louis Masters | 76 | - | Member of Clinical & Scientific Advisory Board |
Derrell D. Porter | 52 | 2023 | Independent Director |
Lennart Mucke | - | 2022 | Member of the Scientific Advisory Board |
Michael A. Weiner | 76 | - | Member of Clinical & Scientific Advisory Board |
Steven T. DeKosky | - | - | Member of Clinical & Scientific Advisory Board |
Daniel J. O'Connell | 53 | 2006 | CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核